Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.05
ANIP's Cash-to-Debt is ranked lower than
97% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ANIP: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
ANIP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: No Debt Max: No Debt
Current: 0.05
Equity-to-Asset 0.49
ANIP's Equity-to-Asset is ranked lower than
72% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ANIP: 0.49 )
Ranked among companies with meaningful Equity-to-Asset only.
ANIP' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.11  Med: 0.77 Max: 0.96
Current: 0.49
-3.11
0.96
Debt-to-Equity 0.87
ANIP's Debt-to-Equity is ranked lower than
83% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. ANIP: 0.87 )
Ranked among companies with meaningful Debt-to-Equity only.
ANIP' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.1  Med: 0.71 Max: 1.71
Current: 0.87
-0.1
1.71
Interest Coverage 1.79
ANIP's Interest Coverage is ranked lower than
97% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIP: 1.79 )
Ranked among companies with meaningful Interest Coverage only.
ANIP' s Interest Coverage Range Over the Past 10 Years
Min: 1.77  Med: 14.2 Max: No Debt
Current: 1.79
Piotroski F-Score: 5
Altman Z-Score: 2.83
Beneish M-Score: -1.91
WACC vs ROIC
15.31%
4.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 13.18
ANIP's Operating Margin % is ranked higher than
82% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ANIP: 13.18 )
Ranked among companies with meaningful Operating Margin % only.
ANIP' s Operating Margin % Range Over the Past 10 Years
Min: -11707.36  Med: -238.32 Max: 42.84
Current: 13.18
-11707.36
42.84
Net Margin % 3.35
ANIP's Net Margin % is ranked higher than
72% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ANIP: 3.35 )
Ranked among companies with meaningful Net Margin % only.
ANIP' s Net Margin % Range Over the Past 10 Years
Min: -11864.14  Med: -234.13 Max: 51.36
Current: 3.35
-11864.14
51.36
ROE % 3.09
ANIP's ROE % is ranked higher than
78% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ANIP: 3.09 )
Ranked among companies with meaningful ROE % only.
ANIP' s ROE % Range Over the Past 10 Years
Min: -320.53  Med: -55.88 Max: 31.63
Current: 3.09
-320.53
31.63
ROA % 1.59
ANIP's ROA % is ranked higher than
78% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ANIP: 1.59 )
Ranked among companies with meaningful ROA % only.
ANIP' s ROA % Range Over the Past 10 Years
Min: -175.65  Med: -16.13 Max: 18.91
Current: 1.59
-175.65
18.91
ROC (Joel Greenblatt) % 31.57
ANIP's ROC (Joel Greenblatt) % is ranked higher than
88% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ANIP: 31.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANIP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6803.87  Med: -133.17 Max: 127.69
Current: 31.57
-6803.87
127.69
3-Year Revenue Growth Rate 23.30
ANIP's 3-Year Revenue Growth Rate is ranked higher than
76% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ANIP: 23.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ANIP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 24 Max: 385
Current: 23.3
0
385
3-Year EBITDA Growth Rate 110.00
ANIP's 3-Year EBITDA Growth Rate is ranked higher than
97% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ANIP: 110.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANIP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -22  Med: 11.5 Max: 267.5
Current: 110
-22
267.5
GuruFocus has detected 3 Warning Signs with ANI Pharmaceuticals Inc $ANIP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANIP's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ANIP Guru Trades in Q3 2016

Paul Tudor Jones 6,500 sh (New)
Jim Simons 190,900 sh (+158.32%)
Third Avenue Management 50,053 sh (unchged)
Joel Greenblatt 4,763 sh (-34.97%)
» More
Q4 2016

ANIP Guru Trades in Q4 2016

Jim Simons 232,700 sh (+21.90%)
Third Avenue Management 49,933 sh (-0.24%)
Joel Greenblatt 4,137 sh (-13.14%)
Paul Tudor Jones 4,600 sh (-29.23%)
» More
Q1 2017

ANIP Guru Trades in Q1 2017

Paul Tudor Jones 8,300 sh (+80.43%)
Jim Simons 278,000 sh (+19.47%)
Third Avenue Management 49,933 sh (unchged)
Joel Greenblatt Sold Out
» More
Q2 2017

ANIP Guru Trades in Q2 2017

Jim Simons 297,400 sh (+6.98%)
Third Avenue Management 49,933 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANIP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-03-31 Sold Out $45.01 - $65.55 $ 50.80-10%0
Third Avenue Management 2016-12-31 Reduce -0.24%$47.51 - $68.96 $ 50.80-17%49,933
Joel Greenblatt 2016-12-31 Reduce -13.14%$47.51 - $68.96 $ 50.80-17%4,137
Joel Greenblatt 2016-09-30 Reduce -34.97%$54.19 - $69.95 $ 50.80-19%4,763
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:MCRB, NAS:KALA, NAS:TYME, NAS:INO, NAS:CALA, NAS:CTMX, NAS:ASMB, NAS:MGNX, NAS:ANAB, NAS:VSAR, NAS:RXDX, NAS:ACHN, NAS:PDLI, NAS:CHRS, NAS:INSY, NAS:JNCE, NAS:IOVA, NAS:DOVA, NAS:PRTK, NAS:NK » details
Headquarter Location:USA
ANI Pharmaceuticals Inc is a specialty pharmaceutical company. The Company, together with its subsidiary is engaged in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

ANI Pharmaceuticals Inc was organized as a Delaware corporation in April 2001. The Company, together with its subsidiary is a specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals products. Its targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. It has two pharmaceutical manufacturing facilities located in Baudette, Minnesota, which are capable of producing oral solid dose products, as well as liquids and topicals, narcotics, and potent products that must be manufactured in a fully-contained environment. It also performs contract manufacturing for other pharmaceutical companies. In addition to laboratories that support all of the requirements of raw materials, finished products, and stability testing, the Company has a 1,000 square foot pilot laboratory offering liquid, suspension and solid dose development capabilities. This pilot laboratory offers a range of analytical capabilities including method development, validation and de-formulation, and is licensed by the Drug Enforcement Administration. Its branded products are Cortenema, Reglan Tablets; and its generic products are Esterified Estrogen with Methyltestosterone Tablets, Fluvoxamine Maleate Tablets, Hydrocortisone Enema, Metoclopramide Syrup and Opium Tincture. Its Esterified Estrogen with Methyltestosterone product is used to treat moderate to severe vasomotor symptoms of menopause, such as hot flashes and heart palpations that are not improved by estrogen medications alone. Its Fluvoxamine Maleate product is used to treat obsessions and compulsions in patients with obsessive-compulsive disorder. Hydrocortisone Enema and its branded equivalent, Cortenema are used for the treatment of ulcerative colitis, especially distal forms, including ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. Its Metoclopramide syrup and its branded equivalent Reglan, in tablet form, are prescribed for periods of four to twelve weeks for heartburn symptoms with gastroesophageal reflux disease when certain other treatments do not work. Its Opium Tincture is used to treat severe diarrhea by slowing the movement of the intestines and decreasing the number and frequency of bowel movements. It owns the trademark names for each of its branded products, Cortenema and Reglan. Its products are sold by four retail pharmacy chains; Walgreens, CVS, RiteAid and Wal-Mart, and are included in the source programs of four national wholesalers; Cardinal, McKesson, AmerisourceBergen and Morris Dickson, which are also wholesale customers of the Company. The Company competes all of its drugs with Creekwood Pharmaceuticals, Endo Pharmaceuticals, Glenmark Pharmaceuticals, Novartis AG, Watson Pharmaceuticals, and Teva Pharmaceuticals USA., Lannett, and Roxane Laboratories

Ratios

vs
industry
vs
history
PE Ratio 112.91
ANIP's PE Ratio is ranked lower than
91% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ANIP: 112.91 )
Ranked among companies with meaningful PE Ratio only.
ANIP' s PE Ratio Range Over the Past 10 Years
Min: 12.74  Med: 28.86 Max: 191.94
Current: 112.91
12.74
191.94
Forward PE Ratio 11.25
ANIP's Forward PE Ratio is ranked lower than
99.99% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. ANIP: 11.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 112.91
ANIP's PE Ratio without NRI is ranked lower than
91% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. ANIP: 112.91 )
Ranked among companies with meaningful PE Ratio without NRI only.
ANIP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.74  Med: 28.86 Max: 191.94
Current: 112.91
12.74
191.94
PB Ratio 3.34
ANIP's PB Ratio is ranked higher than
59% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ANIP: 3.34 )
Ranked among companies with meaningful PB Ratio only.
ANIP' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 4.23 Max: 33.97
Current: 3.34
0.83
33.97
PS Ratio 3.74
ANIP's PS Ratio is ranked higher than
76% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ANIP: 3.74 )
Ranked among companies with meaningful PS Ratio only.
ANIP' s PS Ratio Range Over the Past 10 Years
Min: 0.82  Med: 10.98 Max: 858.69
Current: 3.74
0.82
858.69
Price-to-Operating-Cash-Flow 30.04
ANIP's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. ANIP: 30.04 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ANIP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.63  Med: 33.93 Max: 711.27
Current: 30.04
13.63
711.27
EV-to-EBIT 35.43
ANIP's EV-to-EBIT is ranked lower than
67% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ANIP: 35.43 )
Ranked among companies with meaningful EV-to-EBIT only.
ANIP' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.7  Med: -0.4 Max: 330.8
Current: 35.43
-33.7
330.8
EV-to-EBITDA 15.88
ANIP's EV-to-EBITDA is ranked higher than
56% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ANIP: 15.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANIP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.4  Med: 1.1 Max: 143.2
Current: 15.88
-43.4
143.2
EV-to-Revenue 4.66
ANIP's EV-to-Revenue is ranked higher than
73% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ANIP: 4.66 )
Ranked among companies with meaningful EV-to-Revenue only.
ANIP' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.9  Med: 8.8 Max: 978.2
Current: 4.66
-2.9
978.2
Shiller PE Ratio 0.15
ANIP's Shiller PE Ratio is ranked higher than
99% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. ANIP: 0.15 )
Ranked among companies with meaningful Shiller PE Ratio only.
ANIP' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0.02  Med: 0.13 Max: 0.21
Current: 0.15
0.02
0.21
Current Ratio 3.99
ANIP's Current Ratio is ranked lower than
57% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ANIP: 3.99 )
Ranked among companies with meaningful Current Ratio only.
ANIP' s Current Ratio Range Over the Past 10 Years
Min: 1.11  Med: 6.34 Max: 30.07
Current: 3.99
1.11
30.07
Quick Ratio 2.49
ANIP's Quick Ratio is ranked lower than
72% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ANIP: 2.49 )
Ranked among companies with meaningful Quick Ratio only.
ANIP' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 6.17 Max: 28.24
Current: 2.49
0.75
28.24
Days Inventory 172.22
ANIP's Days Inventory is ranked lower than
60% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. ANIP: 172.22 )
Ranked among companies with meaningful Days Inventory only.
ANIP' s Days Inventory Range Over the Past 10 Years
Min: 55.94  Med: 148.04 Max: 300.6
Current: 172.22
55.94
300.6
Days Sales Outstanding 128.14
ANIP's Days Sales Outstanding is ranked lower than
77% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ANIP: 128.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANIP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.11  Med: 101.11 Max: 151.83
Current: 128.14
11.11
151.83
Days Payable 16.19
ANIP's Days Payable is ranked lower than
71% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. ANIP: 16.19 )
Ranked among companies with meaningful Days Payable only.
ANIP' s Days Payable Range Over the Past 10 Years
Min: 16.19  Med: 69.4 Max: 2968.67
Current: 16.19
16.19
2968.67

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.40
ANIP's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ANIP: -6.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANIP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -65.4  Med: -34.25 Max: -6.4
Current: -6.4
-65.4
-6.4

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.34
ANIP's Price-to-Median-PS-Value is ranked higher than
87% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ANIP: 0.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANIP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 1.76 Max: 118.13
Current: 0.34
0.1
118.13
Earnings Yield (Greenblatt) % 2.81
ANIP's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ANIP: 2.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANIP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5565.9  Med: -3.8 Max: 8709
Current: 2.81
-5565.9
8709

More Statistics

Revenue (TTM) (Mil) $158.12
EPS (TTM) $ 0.45
Beta2.51
Short Percentage of Float10.53%
52-Week Range $42.23 - 69.85
Shares Outstanding (Mil)11.65

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 182 212 235 255
EPS ($) 3.83 4.48 5.03 5.98
EPS without NRI ($) 3.83 4.48 5.03 5.98
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ANIP

Headlines

Articles On GuruFocus.com
ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5 Sep 01 2017 
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2017 Financ Jul 27 2017 
Options trade ideas for ANI Pharmaceuticals, Facebook, Gilead Sciences, Hilton Worldwide and Shutter Jul 26 2017 
ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets Jun 20 2017 
ANI Pharmaceuticals Announces Launch of Pindolol Tablets May 08 2017 
ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2017 Highlights and Reaffirms Gui May 04 2017 
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2017 Financial Results Apr 27 2017 
ANI Pharmaceuticals Announces Launch of Indapamide Tablets Apr 19 2017 
Context Capital Management's Top Sales in Q2 2015 Jul 17 2015 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 

More From Other Websites
ETFs with exposure to ANI Pharmaceuticals, Inc. : September 19, 2017 Sep 19 2017
ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 Sep 05 2017
ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US :... Sep 01 2017
ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100... Sep 01 2017
3 Top Small-Cap Stocks to Buy in August Aug 21 2017
ANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : August 16, 2017 Aug 16 2017
Edited Transcript of ANIP earnings conference call or presentation 3-Aug-17 2:30pm GMT Aug 12 2017
ETFs with exposure to ANI Pharmaceuticals, Inc. : August 8, 2017 Aug 08 2017
ANI Pharmaceuticals to Present at the Canaccord Genuity 37th Annual Growth Conference Aug 08 2017
ANI posts 2Q profit Aug 03 2017
ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ANIP-US : August... Aug 03 2017
ANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms... Aug 03 2017
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2017... Jul 27 2017
ETFs with exposure to ANI Pharmaceuticals, Inc. : July 10, 2017 Jul 10 2017
ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : July... Jul 10 2017
ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : June... Jun 27 2017
ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets Jun 20 2017
ETFs with exposure to ANI Pharmaceuticals, Inc. : June 19, 2017 Jun 19 2017
ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}